Pros | - | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | - | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 3 Years | 12 Years | ||
Fund Size | 214 Cr | 8081 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.47% | 0.91% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | Nifty Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 40 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (16.22%) Divi's Laboratories Ltd (5.96%) Lupin Ltd (5.78%) Suven Pharmaceuticals Ltd (5.39%) Apollo Hospitals Enterprise Ltd (5.16%) | Sun Pharmaceuticals Industries Ltd (13.43%) Divi's Laboratories Ltd (9.28%) Lupin Ltd (7.27%) Cipla Ltd (5.71%) Apollo Hospitals Enterprise Ltd (5.31%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (95.43%) Basic Materials (3.54%) Industrial (1.03%) | Health (100%) | ||
Equity % | 97.95% | 99.46% | ||
Debt % | - | - | ||
P/E | 37.64 | 35.57 | ||
P/B | 5.87 | 5.87 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 2.51% | 3.89% | ||
3-Month Return | 4.89% | 7.52% | ||
6-Month Return | -3.53% | -1.67% | ||
1-Year Return | 20.01% | 17.52% | ||
3-Year Return | 21.39% | 21.24% | ||
5-Year Return | - | 23.82% |
Sharpe | 0.84 | 0.81 | ||
Alpha | 2.89 | 0.5 | ||
Beta | 0.91 | 0.9 | ||
Standard Deviation | 16.41 | 15.85 | ||
Information Ratio | 0.51 | -0.21 |
Description | ITI Pharma and Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | - | Sailesh Raj Bhan,Kinjal Desai |